Delving into the Latest Updates on Seefunge Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Eye Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

COX-2(Cyclooxygenase-2)	1
mAChRs(Muscarinic acetylcholine receptor)	1

The clinical trial aims to test the effectiveness and safety of two low-dose atropine sulfate eye drops for delaying myopia progression in children and adolescents.
Primary Objective: evaluate the effectiveness of 0.01% and 0.02% atropine sulfate eye drops for 96 weeks compared to placebo in delaying myopia progression in children and adolescents. Secondary Objective: evaluate the safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) in delaying myopia progression in children and adolescents.
Exploratory Objective:
1. the efficacy and safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) for 144 weeks.
2. evaluate the rebound effect of two low-concentration atropine sulfate eye drops (0.01%/0.02%) after discontinuation.

Start Date15 Jun 2024

Sponsor / Collaborator

Seefunge Pharmaceutical Technology Co., Ltd.

CTR20213071

/ CompletedNot Applicable

羟苯磺酸钙片健康人体生物等效性研究（空腹）

[Translation] Bioequivalence study of calcium dobesilate tablets in healthy volunteers (fasting)

主要试验目的：在中国健康受试者中评价单次空腹服用宁夏康亚药业股份有限公司生产的羟苯磺酸钙片0.5g（规格：0.25g/片；受试制剂）和OMpharma S.A.生产的羟苯磺酸钙片500mg（商品名：Doxium；规格：250mg/片；参比制剂）的生物等效性；次要试验目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary study objective: To evaluate the bioequivalence of a single fasting dose of 0.5 g calcium dobesilate tablets (specification: 0.25 g/tablet; test preparation) produced by Ningxia Kangya Pharmaceutical Co., Ltd. and 500 mg calcium dobesilate tablets (trade name: Doxium; specification: 250 mg/tablet; reference preparation) produced by OMPharma S.A. in healthy Chinese subjects; Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date06 Mar 2022

Sponsor / Collaborator

Seefunge Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Seefunge Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Seefunge Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Seefunge Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Seefunge Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Phase 3

Login to view more data